Similarly, our in vivo studies in mice with p53/MCA sarcomas demonstrated that intratumoral injection of CpG as a TLR9 agonist in conjunction with radiotherapy significantly improved response compared with either treatment alone as measured by tumor growth delay. The gene discussed is TP53; the disease is neoplasm.